Premium
Repurposing Anticancer Drugs To Tackle Malaria
Author(s) -
Le Govic Yohann,
Houzé Sandrine,
Papon Nicolas
Publication year - 2021
Publication title -
chemmedchem
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.817
H-Index - 100
eISSN - 1860-7187
pISSN - 1860-7179
DOI - 10.1002/cmdc.202100176
Subject(s) - malaria , artemisinin , repurposing , plasmodium falciparum , histone deacetylase , context (archaeology) , drug repositioning , infectious disease (medical specialty) , drug discovery , pharmacology , drug resistance , biology , medicine , drug , disease , immunology , bioinformatics , histone , microbiology and biotechnology , genetics , ecology , paleontology , pathology , gene
Despite considerable efforts, malaria remains one of the most devastating infectious disease worldwide. In the absence of an effective vaccine, the prophylaxis and management of Plasmodium infections still rely on the therapeutic use of antimalarial agents. However, the emergence of resistant parasites has jeopardized the efficiency of virtually all antimalarial drugs, including artemisinin combination therapies (ACTs). Thus, there is an urgent need for innovative treatments with novel targets to avoid or overcome drug resistance. In this context, Huang & colleagues prioritized compounds that can block the activity of epigenetic enzymes, and described the discovery of a selective P. falciparum histone deacetylase (HDAC) inhibitor with high activity against various stages of the parasite. These findings may pave the way toward developing new lead compounds with broad‐spectrum activity, thus facilitating malaria treatment and elimination.